Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

Announcement:

Resources to PDT/PCI related research, 2017

 

The Norwegian Radium Hospital Research Foundation will also for 2017 distribute resources to photodynamic therapy and photochemical internalization (PDT/PCI) related research. In 2016 various research projects within this field were founded with a total of NOK 1,79 million. Employees at the Oslo University Hospital are welcome to apply.
The closing date for applications is February 28th, 2017.

 
 

Announcement: Nominating outstanding scientists, closing date March 1st:

Excellent Researcher Award and Early Career Award 2017

 
From the 2016 ceremony: Pål Aukrust (Excellent Researcher Award) flanked by Therese Seierstad og Espen Melum (both Early Career Awards)
From the 2016 ceremony: Pål Aukrust (Excellent Researcher Award) flanked by Therese Seierstad og Espen Melum (both Early Career Awards)

 Oslo University Hospital hereby announce research awards in the following two catagories for 2017:

  • Excellent Researcher Award (one prize, 300.000 NOK)
  • Early Career Award (two prizes of 150.000 NOK each)

The candidate must be employed by Oslo University Hospital or University of Oslo, and be a member of a research group at Oslo University Hospital/University of Oslo.

 
 

Findings from Rusten group published in Nature on microenvironmental autophagy draw nationwide attention

 
First author Nadja Katheder and senior author Tor Erik Rusten
First author Nadja Katheder and senior author Tor Erik Rusten

Nadja Katheder and collaborators in the lab of Tor Erik Rusten, the Department of Molecular Cell Biology, and CCB has published an article entitled "Microenvironmental autophagy supports tumor growth", in an advanced online publication 11th of January in the journal Nature (journal impact factor 41.46). 
It is known that transformed tumor cells rewire growth and metabolism to support their own growth. How these changes occur in animals, however are poorly understood. In the published study, Katheder and co-workers show how malignant tumors coerce neighboring microenvironmental cells to support their own growth.
The findings have been subject to news coverage by the Norwegian national broadcasting corporation (NRK).

 
 

Story picked up by Science Translational Medicine as "Editor's choice":

New insight into the origin of disseminated tumor cells in breast cancer published in Genome Biology

 
Elen K. Møller, joint first author
Elen K. Møller, joint first author

Elen Kristine Møller, postdoc at the Department of Cancer Genetics, studied during her PhD project the fate of disseminated tumor cells (DTCs). In a collaborative study among OUS, University of Chicago, University of Leuven and the Francis Crick Institute it is revealed that breast cancer cells break away and spread to other parts of the body relatively late on in breast tumor development.
The findings are published in the December 9th issue of Genome Biology (journal impact factor 11.3), in an article entitled "Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing".

Update: The story has become the "Editors Choice" in the January 4th issue of Science Translational Medicine

 
 

Norsk Hydro’s Fund for Cancer Research Lecture January 16th 10:45

Channing J. Der

 
Channing J. Der
Channing J. Der

The Norsk Hydro’s Fund for Cancer Research Lecture January 16th 10:45 - 12:00 in the Auditorium (K-building) at Montebello will be held by the prominent scientist Channing J. Der from UNC Lineberger Comprehensive Cancer Center, Chapel Hill.
Title of his talk:
"Drugging undruggable RAS for cancer treatment"

Dr. Channing J. Der is recognized internationally for his contribution to the discovery and research of the Ras family of oncoproteins.

 
 

Commentary article from Arne Klungland in Nature Methods on epitranscriptome analysis

 
Arne Klungland
Arne Klungland

In the Nature Methods (journal impact factor 25.3) January 2017 issue “Epitranscriptome analysis” is presented as the method of the year. In recent years, it has become clear that RNA molecules, including mRNAs, can be dynamically modified. Thus, this allows for a new strategy for gene regulation with vital biological consequences. Epitranscriptome analysis relates to methods that can profile RNA modifications in a sequence specific manner. In a commentary to this discovery, Klungland and co-workers from Department of Microbiology and Department of Gynecology, OUS, discuss the role of such modifications for the maturation of sperm and egg (meiosis) and pluripotent cells.

 
 

New knowledge about Wee1 and Chk1 inhibitors revealed by a flow cytometry-based compound screen

 
1st author Sissel Hauge and 2nd author Christian Naucke
1st author Sissel Hauge and 2nd author Christian Naucke

In a new study published in Oncotarget, Hauge et al. found an explanation for why combined inhibition of Chk1 and Wee1 gives synergistic anti-cancer effects.

Inhibitors of Wee1 and Chk1 kinases are currently in clinical trials in combination with radiation- or chemotherapy, due to their roles in inhibition of cell cycle checkpoints and DNA repair. Recent preclinical studies have shown synergistic effects of simultaneous Wee1 and Chk1 inhibition, but the mechanisms behind this synergy were not known.

 
 

Research funding from South-Eastern Norway Regional Health Authority for 2017

 

The board of the South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has distributed financial resources to new research projects for 2017. Of the in total 568 incoming applications 121 new projects were granted support.
A substantial amount of the resources goes to young researchers. Support is given to a number og doctoral and post doctoral stipendiates, as well as to researcher grants and career grants. The latter category is for young outstanding researchers planning to establish an independent research group.

 
 

Educating future cancer researchers from Ullern high school

 
Photo: Åsmund H. Eikenes
Photo: Åsmund H. Eikenes

As part of the collaboration between Oslo Cancer Cluster and Ullern high shool, a total of 40 students visited six different laboratories at the Oslo University Hospital and the National Institute for Public Health last week. A journalist from Framtida.no interviewed the six students who visited the Department for Tumor biologi. Researchers Siri Tveito and Karen-Marie Heintz guided them through immunoflourescence, PCR, gel electrophoresis and other techniques in the lab, and the students were eager to learn about the life of a cancer researcher.

 
 

Novel cancer immunotherapy published in Cancer Research, with cover illustration

 
Dec. 1 issue of Cancer Research. <br>First author Kristina Berg Lorvik and senior author Alexandre Corthay
Dec. 1 issue of Cancer Research.
First author Kristina Berg Lorvik and senior author Alexandre Corthay

Collaborative efforts by researchers at the Department of Immunology and the Department of Pathology revealed the unexpected potential of tumor-specific Th2 cells for cancer immunotherapy by adoptive cell transfer (ACT) in mice.
The study was published in the December 1st 2016 issue of Cancer Research, the flagship journal of the American Association for Cancer Research. An immunofluorescence microscopy image from the paper was selected to illustrate the journal cover.